DLin-MC3-Containing mRNA Lipid Nanoparticles Induce an Antibody Th2-Biased Immune Response Polarization in a Delivery Route-Dependent Manner in Mice.
Th2/Th1 polarization
administration routes
gag HIV-1
heterologous protein boost
lipid nanoparticles
mRNA-vaccine
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
21 Mar 2023
21 Mar 2023
Historique:
received:
17
02
2023
revised:
13
03
2023
accepted:
18
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
mRNA-based vaccines have made a leap forward since the SARS-CoV-2 pandemic and are currently used to develop anti-infectious therapies. If the selection of a delivery system and an optimized mRNA sequence are two key factors to reach in vivo efficacy, the optimal administration route for those vaccines remains unclear. We investigated the influence of lipid components and immunization route regarding the intensity and quality of humoral immune responses in mice. The immunogenicity of HIV-p55Gag encoded mRNA encapsulated into D-Lin-MC3-DMA or GenVoy-ionizable lipid-based LNPs was compared after intramuscular or subcutaneous routes. Three sequential mRNA vaccines were administrated followed by a heterologous boost composed of p24-HIV protein antigen. Despite equivalent IgG kinetic profiles of general humoral responses, IgG1/IgG2a ratio analysis showed a Th2/Th1 balance toward a Th1-biased cellular immune response when both LNPs were administrated via the intramuscular route. Surprisingly, a Th2-biased antibody immunity was observed when DLin-containing vaccine was injected subcutaneously. A protein-based vaccine boost appeared to reverse this balance to a cellular-biased response correlated to an increase in antibody avidity. Our finding suggests that the intrinsic adjuvant effect of ionizable lipids appears to be dependent on the delivery route used, which could be relevant to reach potent and long-lasting immunity after mRNA-based immunization.
Identifiants
pubmed: 36986871
pii: pharmaceutics15031009
doi: 10.3390/pharmaceutics15031009
pmc: PMC10058601
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Agence Nationale de Recherches sur le Sida et les Hépatites Virales
ID : ECTZ60600, ECTZ 119388, ECTZ 16031, ECTZ 160315 and ECTZ 119453
Organisme : European Union's Horizon 2020 research and innovation program
ID : 751061
Organisme : Sidaction
ID : 11623
Organisme : Agence Nationale de la Recherche
ID : 192974, ANR 616-CE20-002-01 554, ANR-21-CE35 60019 and Eranet ICRAD-Nuc NanoFish/ANR-21-ICRD-0009
Organisme : Agence Nationale de la Recherche
ID : ANR-21-ESRE-0023
Déclaration de conflit d'intérêts
S.G. is a Precision Nanosystem intern collaborator, and B.V. is a founding member and a shareholder of Adjuvatis. Those companies had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
Immunity. 2005 Aug;23(2):165-75
pubmed: 16111635
Commun Biol. 2021 Aug 11;4(1):956
pubmed: 34381159
Signal Transduct Target Ther. 2022 Jul 19;7(1):243
pubmed: 35853864
Front Immunol. 2022 Jul 22;13:945706
pubmed: 35935984
J Control Release. 2019 Aug 10;307:211-220
pubmed: 31170464
Vaccine. 2021 Oct 8;39(42):6210-6212
pubmed: 34531083
Vaccines (Basel). 2022 Aug 25;10(9):
pubmed: 36146463
Pharmaceut Med. 2022 Feb;36(1):11-20
pubmed: 35094366
Biochim Biophys Acta. 2001 Feb 9;1510(1-2):152-66
pubmed: 11342155
Front Cell Dev Biol. 2022 Jul 13;10:901510
pubmed: 35912117
Cell Rep. 2021 Aug 10;36(6):109504
pubmed: 34352226
Mol Ther Nucleic Acids. 2019 Apr 15;15:1-11
pubmed: 30785039
Nat Med. 2021 Dec;27(12):2085-2098
pubmed: 34848888
Nat Med. 2021 Dec;27(12):2234-2245
pubmed: 34887575
J Control Release. 2022 Apr;344:50-61
pubmed: 34953981
Discoveries (Craiova). 2021 Mar 5;9(1):e122
pubmed: 33969180
Adv Drug Deliv Rev. 2022 Sep;188:114416
pubmed: 35787388
Nat Med. 2021 Dec;27(12):2082-2084
pubmed: 34887576
Nat Rev Drug Discov. 2015 Nov;14(11):781-803
pubmed: 26471369
Chem Rev. 2021 Oct 27;121(20):12181-12277
pubmed: 34279087
Postgrad Med J. 2021 Jun;97(1148):400
pubmed: 33589486
Nat Nanotechnol. 2020 Apr;15(4):313-320
pubmed: 32251383
ACS Nano. 2021 Apr 27;15(4):6709-6722
pubmed: 33754708
NPJ Vaccines. 2022 Jun 28;7(1):71
pubmed: 35764661
Nature. 2021 Sep;597(7878):606-607
pubmed: 34548661
Science. 1990 Mar 23;247(4949 Pt 1):1465-8
pubmed: 1690918
Nanomedicine. 2017 May;13(4):1377-1387
pubmed: 28038954
Immunity. 2020 Oct 13;53(4):724-732.e7
pubmed: 32783919
Nano Today. 2014 Apr 1;9(2):223-243
pubmed: 25132862
Nano Lett. 2018 Mar 14;18(3):2148-2157
pubmed: 29489381
Pharmaceutics. 2020 Nov 15;12(11):
pubmed: 33203082
Vaccines (Basel). 2021 Feb 07;9(2):
pubmed: 33562203
J Control Release. 2014 Feb 28;176:115-22
pubmed: 24384300
NPJ Vaccines. 2021 Apr 9;6(1):50
pubmed: 33837212
Immunity. 2021 Dec 14;54(12):2877-2892.e7
pubmed: 34852217
J Control Release. 2015 Nov 10;217:345-51
pubmed: 26264835
J Control Release. 2021 Jul 10;335:237-246
pubmed: 34019945
Cell Rep. 2022 Mar 15;38(11):110514
pubmed: 35294883
Mol Ther. 2017 Jul 5;25(7):1467-1475
pubmed: 28412170
Commun Biol. 2023 Feb 17;6(1):188
pubmed: 36805684
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):129-137
pubmed: 26900977
J Control Release. 2013 Apr 10;167(1):60-7
pubmed: 23352911
J Virol. 2006 Mar;80(6):3122-5
pubmed: 16501126
Environ Sci Pollut Res Int. 2020 Jun;27(18):22336-22352
pubmed: 32347486
Viruses. 2022 Feb 15;14(2):
pubmed: 35215994
PLoS One. 2008 Jan 09;3(1):e1424
pubmed: 18183304
Nature. 2022 Mar 18;:
pubmed: 35304887
Mol Ther Nucleic Acids. 2019 Apr 15;15:36-47
pubmed: 30974332
Eur J Med Chem. 2022 Jan 5;227:113910
pubmed: 34689071
Nat Clim Chang. 2022;12(9):869-875
pubmed: 35968032
J Virol. 2014 Jun;88(12):6959-69
pubmed: 24719412
Hum Vaccin Immunother. 2017 Jan 2;13(1):17-18
pubmed: 28125375
Pharmaceutics. 2022 Jun 18;14(6):
pubmed: 35745869
Signal Transduct Target Ther. 2022 May 21;7(1):166
pubmed: 35597779